Canaccord analyst John Newman initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $9 price target The firm expects Roche to proceed with clinical studies for Lineage’s lead asset OpRegen for the treatment of geographic atrophy. This should drive upside in the shares, the analyst tells investors in a research note. Canaccord also expects continued positive data for Lineage’s OPC1 in acute and chronic spinal cord injury.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Lineage Cell Therapeutics announces formation of Scientific Advisory Board
- Lineage Cell Therapeutics management to meet with Craig-Hallum
- Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley
- Lineage Cell launches cell therapy program in corneal endothelial disease
- Lineage Therap Expands ATM Equity Offering Capacity